Skip to Main Content

Paper Details

A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer.
Biochem Pharmacol
1
2022
Author NameAffiliation
John W M MartensErasmus MC Cancer Institute, Erasmus University Medical Center
  • 1 - 1

Datasets

Release 1.2